ASAndreas Schuck

Andreas Schuck

*This is an algorithmically generated author record based on publicly available information.

Andreas Schuck has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 6 February 2009
      • Vol. 28, 3885-90

    Perioperative high-dose rate brachytherapy using a bendy applicator (flab): treatment results of 74 patients.

    by Tobias Bölling, Patrick Schüller, Bernd Distelmaier, Andreas Schuck, Iris Ernst, Georg Gosheger, Winfried Winkelmann, Uta Dirksen, Heribert Jürgens, Hans-Lars Kronholz, et al.

    Radiotherapy plays a pivotal role in tumor treatment. Brachytherapy as an additional radiation technique allows local dose increments in areas at high risk of local failure. Our past 15-year experience with tissue-equivalent bendy applicator brachytherapy at the University Hospital Münster, Germany was reviewed. A series of 74 consecutive patients who had mainly been treated for sarcomas with perioperative brachytherapy was analyzed with a focus on local relapse-free survival and side-effects. The 5-year local control rate was 73% in primary treatment situations with a significant influence of additional external irradiation, surgical margin depth and tumor entity. Late sequelae of combined modality treatment were observed in 40 patients (54%) and mainly concerned wound healing (n = 18, 24%). A high-risk collective, in view of local failure, showed adequate local control rates as well as acceptable late sequelae. Flab brachytherapy is a good treatment option to achieve local radiation dose increments in patients at high risk of local failure.


  • Open Access

    Study protocol of the German "Registry for the Detection of Late Sequelae after Radiotherapy in Childhood and Adolescence" (RiSK)

    by Tobias Bolling, Andreas Schuck, Hildegard Pape, Christian Rube, Barbara Pollinger, Beate Timmermann, Rolf D Kortmann, Karin Dieckmann, Normann Willich

    Background: Late effects after radiotherapy in childhood and adolescence have mainly been characterized retrospectively with small patient numbers. However, these analyses are limited due to little information regarding organ dose levels in many cases. To overcome this limitation, the German Group of Paediatric Radiation Oncology (APRO) established the „Registry for the evaluation of late side effects after radiation in childhood and adolescence” (RiSK). The study protocol and the documentation forms are given in this publication. Methods/Design: Radiation parameters including detailed organ doses as well as toxicity evaluations are collected prospectively from centres all over Germany. Standardized documentation forms are used. These forms are given in an English and German version as additional files to this publication. Documentation is planned for all children who receive radiotherapy in one of the therapy trials of the "German Society of Paediatric Oncology and Haematology (GPOH)". The study started in a pilot phase in June 2001 in few centres. Since 2004 documentation has been performed all over Germany and is still on-going. Discussion: To our knowledge, "RiSK" is the only multi-centre study that evaluates radiation associated side effects prospectively with detailed information about organ dose levels. With ongoing recruitment and prolongation of follow-up powerful data will be obtained in a few years. A broad use and international cooperation are welcome.


  • Open Access

    High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy

    by Benedikt Leidinger, Thomas Heyse, Andreas Schuck, Horst Buerger, Philipp Mommsen, Thomas Bruening, Susanne Fuchs, Georg Gosheger

    Background: The risk of metastasis and the survival in patients with primary extremity soft tissue sarcomas is worse when tumour size is large and the grade of malignancy is high. Such tumours may receive chemotherapy and/or radiation therapy (RTX) for optimising local control. Irradiation can either be applied preoperatively or after tumour resection. The question arises if the kind of RTX in the absence of chemotherapy influences the outcome concerning local control, metastatic disease, survival and complications. Methods: We retrospectively reviewed the clinical outcome of 233 patients with a primary extremity soft tissue sarcoma treated between 1990 – 2000 with a mean follow-up of 35.8 (4–120) months in our institute. 41 patients had high grade, deep and large tumours (>8 cm), an AJCC stage III (no evidence of metastasis prior to treatment) and were treated with limb salvage surgery and irradiation but stayed without additional chemotherapy. Two groups of patients were compared: the first group received postoperative RTX after tumour resection (n = 33); the second group was treated with preoperative RTX (n = 8). Both groups did not differ concerning clinical parameters. We analysed primary and secondary outcomes. Results: 56% (23/41) of the population developed metastatic disease, 24% (10/41) local recurrence. The risk of metastasis was higher in the group with preoperative irradiation (p = 0.046). The overall (p = 0.0248) and relapse free survival (p = 0.104) were worse in this group. The delay to tumour resection amounted 8 weeks on average in the preoperative group. Local control was not different (p = 0.38) in both study groups. Wound infections and other combined therapy related complications were equally distributed (p = 0.22). Conclusion: Without chemotherapy there remains a high risk of metastasis in AJCC grade 3 patients. In high risk patients treated without chemotherapy the elapsed time to tumour resection after preoperative radiation might contribute to the development of metastasis. This outcome may support the thesis that a combination of RTX and offensive multimodal treatment protocols is advantageous in such a subset of patients


  • Strahlentherapie bei Knochentumoren

    by D. Schulz-Ertner, A. Schuck

  • Radiotherapy in Ewing tumors of the vertebrae: Treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials

    by Andreas Schuck, Susanne Ahrens, Ines von Schorlemer, Michaela Kuhlen, Michael Paulussen, Andrea Hunold, Georg Gosheger, Winfried Winkelmann, Jürgen Dunst, Normann Willich, et al.


  • Ovarian Function Following Pelvic Irradiation in Prepubertal and Pubertal Girls and Young Adult Women

    by Andreas Schuck, Victoria Hamelmann, Jürgen H. Brämswig, Stefan Könemann, Claudia Rübe, Stefan Hesselmann, Dorothea Riesenbeck, Ekkehard Horst, Tobias Bölling, Michael Paulussen, et al.

    To analyze the effect of pelvic radiotherapy on ovarian function in prepubertal and pubertal girls and young adult women. In a retrospective monoinstitutional analysis, patients < 30 years of age at diagnosis were included who had been irradiated between 1979 and 1998. The main tumor types were Hodgkin’s disease (38%), Ewing’s sarcoma (20%) and nephroblastoma (11%). Patients were classified into three groups according to the position of the ovary in relation to the radiation portals. Group 1 was defined by direct irradiation of both ovaries. Group 2 patients were included with both ovaries potentially located in the radiation portals. In group 3, at least one ovary was not directly irradiated. The median follow-up was 128 months. 16 of 55 analyzed patients were categorized in group 1. In ten of these patients, hormone status was evaluable. The ovarian doses were ≥ 15 Gy. Except for one patient treated with 15 Gy all developed hormone failure. Eight of 14 patients of group 2 were evaluable. Seven of these patients developed ovarian failure. 19 of 24 patients in group 3 were evaluable. Nine of these patients developed ovarian failure. The observed difference in the rate of ovarian failure between the groups is statistically significant (p = 0.045). All patients receiving > 15 Gy to the ovaries developed hormone failure. In one case of a patient receiving an ovarian dose of 15 Gy, hormone failure was not found. In case of pelvic irradiation excluding at least one ovary, approximately half of the patients developed ovarian dysfunction, probably also due to the effects of polychemotherapy. Analyse des Einflusses einer Beckenbestrahlung auf die Ovarialfunktion bei Mädchen und jungen Frauen. In einer retrospektiven monoinstitutionalen Analyse wurden Patientinnen evaluiert, die in den Jahren 1979–1998 in der Klinik für Strahlentherapie des Universitätsklinikums Münster bestrahlt worden waren und bei Therapie < 30 Jahre waren. Die häufigsten Tumorentitäten waren Morbus Hodgkin (38%), Ewing-Sarkome (20%) and Nephroblastome (11%). Die Patientinnen wurden in drei Gruppen eingeteilt. Bei Patientinnen der Gruppe 1 wurden beide Ovarien bestrahlt. Bei Patientinnen der Gruppe 2 wurden beide Ovarien potentiell bestrahlt, und in Gruppe 3 wurde mindestens ein Ovar nicht bestrahlt. Die mediane Nachbeobachtungszeit beträgt 128 Monate. Von den analysierten Patientinnen wurden 16 in Gruppe 1 klassifiziert. Bei zehn dieser Patientinnen war der Hormonstatus evaluierbar. Die Ovarialdosis lag bei ≥ 15 Gy. Bis auf eine Patientin, die mit 15 Gy bestrahlt wurde, entwickelten alle weiteren Patientinnen eine Ovarialinsuffizienz. Von 14 Patientinnen der Gruppe 2 waren acht evaluierbar. Sieben davon wiesen eine Ovarialinsuffizienz auf. 19 von 24 Patientinnen in Gruppe 3 waren evaluierbar. Neun davon entwickelten eine Ovarialinsuffizienz. Der Unterschied zwischen den drei Gruppen in Bezug auf das Auftreten einer Insuffizienz ist signifikant (p = 0,045). Alle Patientinnen, die mit > 15 Gy an den Ovarien belastet wurden, entwickelten eine Hormoninsuffizienz. Eine Patientin mit 15 Gy Ovarialbelastung wies keine Ovarialinsuffizienz auf. Wenn mindestens ein Ovar nicht bestrahlt wurde, lag die Insuffizienzrate bei etwa 50%, wahrscheinlich mitbedingt durch die Chemotherapie.


  • Strahlentherapie des Schilddrüsenkarzinoms

    by A. Schuck, M. Biermann, O. Schober, N. Willich


    • 28 July 2004
      • Vol. 24, 1637-44

    Changed adhesion molecule profile of Ewing tumor cell lines and xenografts under the influence of ionizing radiation.

    by Stefan Könemann, Johann Malath, Tobias Bölling, Astrid Kolkmeyer, Kirsten Janke, Dorothea Riesenbeck, Stefan Hesselmann, Tan Phu Nguyen, Raihanatou Diallo, Josef Vormoor, et al.

    Adhesion molecules are involved in cell-cell and cell-matrix interactions and may be informative to characterize intercellular mechanisms of invasion and metastasis. This study was performed to characterize radiation-induced changes in the adhesion molecule profile of Ewing tumor subpopulations on a single cell level. In the present study, two Ewing tumors were characterized in vitro 4, 24 and 72 hours after radiation with 5 Gy and in vivo in a xenograft model 4, 6 and 15 days after radiation with 30 Gy, together with non-irradiated controls, by five parameter flow cytometry. Directly fluorescence-conjugated antibodies that were directed against adhesion molecules (LFA-1 (CD11a), HCAM (CD44), VLA-2 (CD49b), ICAM-1 (CD54), NCAM (CD56), LECAM-1 (CD62L) and CD86) were used. Annexin V and 7-AAD were used to characterize radiation-induced apoptosis. Tumor cell subpopulations were identified by the expression of adhesion molecules, apoptotic markers and DNA content. Heterogeneous changes of the adhesion molecule profile were identified on tumor cell subpopulations after radiation. The expression of CD11a and CD62L correlated with the expression of apoptosis-associated markers. The changes of flow cytometric profile under radiation may potentially correlate with a changed metastatic potential of tumor cell subpopulations.


  • Group II Rhabdomyosarcoma and Rhabdomyosarcomalike Tumors: Is Radiotherapy Necessary?

    by Andreas Schuck, Adrian C. Mattke, Bernhard Schmidt, Denise S. Kunz, Dieter Harms, Robert Knietig, Joern Treuner, Ewa Koscielniak

    Purpose: In the prospective Cooperative Soft Tissue Sarcoma Study Group (CWS) 81, 86, 91, and 96 trials, radiotherapy was omitted in some patients with rhabdomyosarcoma and rhabdomyosarcoma-like tumors within Intergroup Rhabdomyosarcoma Study (IRS) group II. This analysis evaluates whether subgroups can be defined for which radiotherapy is not necessary. Patients and Methods: Two hundred three patients who were registered between January 1981 and December 1998 were eligible for evaluation. Radiotherapy was given depending on tumor location, histology, and whether a secondary complete resection could be performed. The recommended radiation doses ranged from 32 to 54 Gy. Results: One hundred ten patients did receive and 93 patients did not receive radiotherapy. The calculated local control after 5 years was 83% with and 65% without radiotherapy (P < .004). Event-free survival (EFS) at 5 years was 76% and 58%, respectively (P < .005). Overall survival (OS) at 5 years was 84% and 77% (P = not significant). The differences in local control were significant for the subgroups of irradiated patients with favorable histology, favorable site, and initial tumor size of less than 5 cm. A trend for improved local control with irradiation was observed for patients with unfavorable site, unfavorable histology, and large primary tumors. EFS was significantly improved for irradiated patients who had unfavorable histology, both favorable and unfavorable tumor sites, and small initial tumors. OS was significantly improved for patients with unfavorable histology through radiation. Conclusion: Local control and EFS in group II patients are improved with radiotherapy. No subgroup could be defined for which the omission of radiotherapy produced outcome equivalent to that of patients who were irradiated.


  • Acute Toxicity of Adjuvant Radiotherapy in Locally Advanced Differentiated Thyroid Carcinoma

    by Andreas Schuck, Martin Biermann, Michaela K. Pixberg, Stefan B. Müller, Achim Heinecke, Otmar Schober, Normann Willich

    The indication for adjuvant postoperative radiotherapy in patients with differentiated thyroid carcinoma (DTC) extending beyond the thyroid capsule has been an issue of controversy during the past 2 decades. No randomized studies evaluating the benefit of radiotherapy have been published so far. In the Multicenter Study Differentiated Thyroid Carcinoma (MSDS), a randomization has been performed concerning external-beam radiotherapy in patients with DTC extending beyond the thyroid capsule (pT4 pN0/1/× cM0, TNM classification, 5th edition, 1997) following surgery and radioiodine therapy. Radiation-associated toxicity has been prospectively evaluated.